肺瘤消积方联合吉非替尼治疗痰瘀互结型晚期非小细胞肺癌的临床疗效  

Clinical efficacy of Feiliu Xiaoji formula combined with gefitinib in treating advanced non-small cell lung cancer of phlegm and blood stasis type

作　　者：陈晶晶 王振强[1] 张庆江 赵阳 赵芳 董雪珊 赵怡然 张瑞 李莹 CHEN Jingjing;WANG Zhenqiang;ZHANG Qingjiang;ZHAO Yang;ZHAO Fang;DONG Xueshan;ZHAO Yiran;ZHANG Rui;LI Ying(Department of Traditional Chinese Medicine,Cangzhou Hospi-tal of Integrated Traditional Chinese and Western Medicine,Cangzhou,061000,Hebei,China;the Second Department of Radiotherapy and Chemotherapy,Cangzhou Hospi-tal of Integrated Traditional Chinese and Western Medicine,Cangzhou,061000,Hebei,China;Department of Oncology,Shi-jiazhuang Ping'an Hospital,Shijiazhuang,050000,Hebei,China;Chengde Medical College,Chengde,067000,Hebei,China;Hebei University,Baoding,071000,Hebei,China;North China University of Science and Technology,Tangshan,063210,Hebei,China;Hebei University of Traditional Chinese Medicine,Shijiazhuang,050000,Hebei,China)

机构地区：[1]河北省沧州中西医结合医院中医内科,河北沧州061000 [2]河北省沧州中西医结合医院放化疗二科,河北沧州061000 [3]石家庄平安医院肿瘤科,河北石家庄050000 [4]承德医学院,河北承德067000 [5]河北大学,河北保定071000 [6]华北理工大学,河北唐山063210 [7]河北中医大学,河北石家庄050000

出　　处：《肿瘤药学》2024年第1期87-92,共6页Anti-Tumor Pharmacy

基　　金：河北省中医药管理局科研计划项目(2019271)。

摘　　要：目的探讨肺瘤消积方联合吉非替尼治疗痰瘀互结型晚期非小细胞肺癌(NSCLC)的临床疗效及对血清肿瘤标志物和炎性因子水平的影响。方法选取2019年2月—2021年2月于我院就诊的痰瘀互结型晚期NSCLC患者100例,根据随机数字表法分为对照组和治疗组(n=50)。对照组患者口服吉非替尼片,治疗组患者在对照组的基础上加用肺瘤消积方,以21 d为1个治疗周期,两组患者均治疗4周期。对比分析两组血清肿瘤标志物和炎性因子水平、生活质量评分、无进展生存期(PFS)、中医症状分级、临床疗效、不良反应。结果治疗后,两组细胞角质蛋白19片段抗原21-1(CYFRA21-1)、糖类抗原19-9(CA19-9)、癌胚抗原(CEA)、白细胞介素-1(IL-1)、IL-6、肿瘤坏死因子-α(TNF-α)水平以及癌症患者生命质量测定量表(QLQ-C30)评分均低于治疗前,且治疗组低于对照组(P<0.05);治疗组PFS显著长于对照组(P<0.05);两组中医症状分级均显著改善,且治疗组优于对照组(P<0.05);治疗组客观缓解率(ORR)、疾病控制率(DCR)(68.00%、84.00%)均显著高于对照组(42.00%、62.00%)(P<0.05);治疗组皮肤反应、腹泻总发生率(22.00%、50.00%)均显著低于对照组(42.00%、74.00%)(P<0.05)。结论肺瘤消积方联合吉非替尼治疗痰瘀互结型晚期NSCLC患者疗效显著,可有效降低患者血清CYFRA21-1、CA19-9、CEA、IL-1、IL-6、TNF-α水平,改善患者病情,且安全性较高。Objective To investigate the clinical efficacy of Feiliu Xiaoji formula combined with gefitinib in treating ad-vanced non-small cell lung cancer(NSCLC)patients of phlegm and blood stasis type and its influences on the levels of se-rum tumor markers and inflammatory factors.Methods One-hundred patients with advanced NSCLC of phlegm and blood stasis type who were treated in our hospital between February 2019 and February 2021 were included and grouped into con-trol group and treatment group(n=50)according to the random number table method.Patients in the control group took gefi-tinib tablets orally,and those in the treatment group received gefitinib tablets plus Feiliu Xiaoji formula.One treatment cy-cle took 21 days,and all patients were treated for 4 cycles.The levels of serum tumor markers and inflammatory factors,the score of quality of life,progression-free survival(PFS),TCM symptom grading,clinical efficacy,and adverse reactions were compared between the two groups.Results After treatment,the levels of cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carbohydrate antigen 19-9(CA19-9),carcinoembryonic antigen(CEA),interleukin-1(IL-1),interleukin-6(IL-6),tu-mor necrosis factor-α(TNF-α),and the score of Quality of Life Questionnaire(QLQ-C30)were lower than those before treatment in both groups,and those of the treatment group were lower than those of the control group(P<0.05).The PFS of the treatment group was obviously longer than that of the control group(P<0.05).The TCM symptom grades in both groups were obviously improved,and those in treatment group were better than in control group(P<0.05).The objective response rate(ORR)and disease control rate(DCR)of the treatment group(68.00%,84.00%)were obviously higher than those of the control group(42.00%,62.00%)(P<0.05).In addition,the total incidences of skin reactions and diarrhea of the treatment group(22.00%,50.00%)were obviously lower than those of the control group(42.00%,74.00%)(P<0.05).Conclusion Feiliu Xiaoji formula combined with gefitinib was effective

关 键 词：肺瘤消积方 吉非替尼 痰瘀互结 非小细胞肺癌 肿瘤标志物 炎性因子 

分 类 号：R734.2[医药卫生—肿瘤]